Prestige BioPharma Limited
Climate Impact & Sustainability Data (2022-07 to 2023-06)
Reporting Period: 2022-07 to 2023-06
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Not disclosed
Environmental Achievements
- Not disclosed
Social Achievements
- Not disclosed
Governance Achievements
- Not disclosed
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Supply chain disruptions due to the Russia-Ukraine conflict and COVID-19 pandemic.
- Delays in clinical trials and product approvals due to the Russia-Ukraine conflict and COVID-19 pandemic.
- Negative opinion from EMA regarding HD201 biosimilar.
Mitigation Strategies
- Monitoring and evaluating the impact of the Russia-Ukraine conflict on business and financial statements.
- Continued investment in biosimilar and antibody drug development to ensure future revenue generation.
- Re-application for HD201 approval to EMA after addressing concerns.
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: EU-GMP
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed